HUE050788T2 - Új gyógyászati kompozíció - Google Patents

Új gyógyászati kompozíció

Info

Publication number
HUE050788T2
HUE050788T2 HUE11849974A HUE11849974A HUE050788T2 HU E050788 T2 HUE050788 T2 HU E050788T2 HU E11849974 A HUE11849974 A HU E11849974A HU E11849974 A HUE11849974 A HU E11849974A HU E050788 T2 HUE050788 T2 HU E050788T2
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
novel pharmaceutical
novel
composition
pharmaceutical
Prior art date
Application number
HUE11849974A
Other languages
English (en)
Inventor
Douglas Demarini
Ngocdiep Le
Francisco Henriquez
Lihong Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE050788(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE050788T2 publication Critical patent/HUE050788T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE11849974A 2010-12-20 2011-12-20 Új gyógyászati kompozíció HUE050788T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20

Publications (1)

Publication Number Publication Date
HUE050788T2 true HUE050788T2 (hu) 2021-01-28

Family

ID=46314827

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE11849974A HUE050788T2 (hu) 2010-12-20 2011-12-20 Új gyógyászati kompozíció
HUE22209107A HUE066526T2 (hu) 2010-12-20 2011-12-20 Új gyógyászati készítmény
HUE22209104A HUE066525T2 (hu) 2010-12-20 2011-12-20 Új gyógyászati készítmény

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE22209107A HUE066526T2 (hu) 2010-12-20 2011-12-20 Új gyógyászati készítmény
HUE22209104A HUE066525T2 (hu) 2010-12-20 2011-12-20 Új gyógyászati készítmény

Country Status (37)

Country Link
US (5) US20130266649A1 (hu)
EP (4) EP4159204B1 (hu)
JP (2) JP6126014B2 (hu)
KR (1) KR101911109B1 (hu)
CN (1) CN103998041B (hu)
AR (2) AR084102A1 (hu)
AU (1) AU2011349422B2 (hu)
BR (1) BR112013015602B1 (hu)
CA (1) CA2822701C (hu)
CL (1) CL2013001779A1 (hu)
CR (1) CR20130352A (hu)
CY (1) CY1123376T1 (hu)
DK (3) DK4159205T3 (hu)
DO (1) DOP2013000138A (hu)
EA (1) EA025198B1 (hu)
ES (2) ES2820536T3 (hu)
FI (2) FI4159205T3 (hu)
HR (3) HRP20240564T1 (hu)
HU (3) HUE050788T2 (hu)
IL (1) IL226855A (hu)
JO (1) JO3594B1 (hu)
LT (3) LT2654736T (hu)
MA (1) MA34883B1 (hu)
MX (1) MX2013007073A (hu)
MY (1) MY170501A (hu)
NZ (1) NZ612157A (hu)
PE (1) PE20140040A1 (hu)
PL (3) PL2654736T3 (hu)
PT (3) PT4159204T (hu)
RS (2) RS65497B1 (hu)
SG (1) SG191054A1 (hu)
SI (3) SI2654736T1 (hu)
TW (1) TWI505828B (hu)
UA (1) UA113158C2 (hu)
UY (1) UY33818A (hu)
WO (1) WO2012088033A2 (hu)
ZA (1) ZA201304189B (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500582UA (en) 2012-08-17 2015-04-29 Hoffmann La Roche Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
CA2891346A1 (en) * 2012-11-30 2014-06-05 Gossett Campbell Pharmaceutical composition comprising trametinib dimethyl sulfoxide
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1(2H)-基苯基乙酰胺的衍生物及其应用
WO2015081566A1 (zh) * 2013-12-06 2015-06-11 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
BR112019002007B1 (pt) * 2016-08-10 2024-01-16 F. Hoffmann-La Roche Ag Composição farmacêutica e uso de uma composição farmacêutica
RU2627692C1 (ru) 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
US10709699B2 (en) 2016-11-25 2020-07-14 Jiangsu Hengrui Medicine Co., Ltd. Pyridone derivative pharmaceutical composition and preparation method thereof
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
AU2020311942A1 (en) 2019-07-11 2022-02-24 Praxis Precision Medicines, Inc. Formulations of T-type calcium channel modulators and methods of use thereof
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANCER IN DOGS
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
EP4444299A1 (en) 2021-12-06 2024-10-16 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
EP2086518A2 (en) * 2006-11-09 2009-08-12 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CA2694646C (en) * 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
RU2470641C2 (ru) * 2007-09-25 2012-12-27 Тева Фармасьютикал Индастриес Лтд. Стабильные составы иматиниба
JP5719770B2 (ja) * 2008-07-08 2015-05-20 ベータ・ファーマ・インコーポレイテッドBeta Pharma, Inc. 塩酸イコチニブ、合成物、結晶学的形態、併用薬及びその用途
US20120322817A1 (en) 2009-09-23 2012-12-20 Melissa Dumble Combination
AU2010298280B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
AU2010298020B8 (en) 2009-09-28 2013-10-10 Glaxosmithkline Llc Combination
RS65800B1 (sr) * 2009-10-16 2024-08-30 Novartis Ag Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
EP2501379B1 (en) 2009-11-17 2016-03-23 Novartis AG Combination
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit

Also Published As

Publication number Publication date
SI2654736T1 (sl) 2020-10-30
TWI505828B (zh) 2015-11-01
US20140154316A1 (en) 2014-06-05
US9271941B2 (en) 2016-03-01
MX2013007073A (es) 2013-09-26
PL4159205T3 (pl) 2024-06-24
ZA201304189B (en) 2014-02-26
BR112013015602B1 (pt) 2022-03-03
AU2011349422A1 (en) 2013-05-02
US20130266649A1 (en) 2013-10-10
US8580304B2 (en) 2013-11-12
EP4159204A1 (en) 2023-04-05
DOP2013000138A (es) 2013-11-30
NZ612157A (en) 2015-05-29
EA201390913A1 (ru) 2014-04-30
PT4159205T (pt) 2024-05-08
ES2982775T3 (es) 2024-10-17
CA2822701C (en) 2018-10-23
AU2011349422B2 (en) 2015-12-10
KR20130130028A (ko) 2013-11-29
SI4159205T1 (sl) 2024-06-28
EA025198B1 (ru) 2016-11-30
TW201249441A (en) 2012-12-16
RS65497B1 (sr) 2024-06-28
DK2654736T3 (da) 2020-09-14
UA113158C2 (xx) 2016-12-26
US20140099365A1 (en) 2014-04-10
JP2014510704A (ja) 2014-05-01
CR20130352A (es) 2013-12-18
RS65496B1 (sr) 2024-06-28
LT2654736T (lt) 2020-09-25
PT4159204T (pt) 2024-05-07
MA34883B1 (fr) 2014-02-01
AR122185A2 (es) 2022-08-24
CN103998041A (zh) 2014-08-20
EP2654736A4 (en) 2015-04-22
PL2654736T3 (pl) 2020-12-14
US20140037726A1 (en) 2014-02-06
PE20140040A1 (es) 2014-02-26
JP6126014B2 (ja) 2017-05-10
IL226855A (en) 2017-04-30
JP2017137299A (ja) 2017-08-10
US9155706B2 (en) 2015-10-13
LT4159205T (lt) 2024-05-10
HUE066526T2 (hu) 2024-08-28
BR112013015602A2 (pt) 2017-02-21
HRP20240563T1 (hr) 2024-08-16
HUE066525T2 (hu) 2024-08-28
EP4159205A1 (en) 2023-04-05
PT2654736T (pt) 2020-09-24
SG191054A1 (en) 2013-08-30
MY170501A (en) 2019-08-08
EP3808343A1 (en) 2021-04-21
AR084102A1 (es) 2013-04-24
EP4159204B1 (en) 2024-02-14
HRP20240564T1 (hr) 2024-09-27
DK4159205T3 (da) 2024-05-13
US9399021B2 (en) 2016-07-26
CL2013001779A1 (es) 2014-06-27
LT4159204T (lt) 2024-05-10
ES2820536T3 (es) 2021-04-21
WO2012088033A3 (en) 2014-03-13
EP2654736A2 (en) 2013-10-30
CN103998041B (zh) 2016-08-17
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
HRP20201409T1 (hr) 2020-11-27
PL4159204T3 (pl) 2024-07-01
WO2012088033A2 (en) 2012-06-28
JO3594B1 (ar) 2020-07-05
CA2822701A1 (en) 2012-06-28
CY1123376T1 (el) 2021-12-31
FI4159204T3 (fi) 2024-04-22
UY33818A (es) 2012-07-31
SI4159204T1 (sl) 2024-06-28
FI4159205T3 (fi) 2024-04-23
EP4159205B1 (en) 2024-02-14
KR101911109B1 (ko) 2018-10-23
US20120183613A1 (en) 2012-07-19

Similar Documents

Publication Publication Date Title
HK1246170A1 (zh) 藥物組合物
IL225457A0 (en) Pharmaceutical composition
SI2619182T1 (sl) Farmacevtski sestavek
ZA201304189B (en) Novel pharmaceutical composition
EP2616076A4 (en) PHARMACEUTICAL COMPOSITIONS
PT2579858E (pt) Composição farmacêutica que contém ivabradina
ZA201301920B (en) Pharmaceutical composition
GB201010453D0 (en) Pharmaceutical composition
EP2635307A4 (en) PHARMACEUTICAL COMPOSITIONS
IL221501A (en) Medicinal product containing miramistine
GB201001911D0 (en) Pharmaceutical composition
EP2560678A4 (en) PHARMACEUTICAL COMPOSITIONS
GB201019775D0 (en) Pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201005403D0 (en) Novel pharmaceutical compositions
EP2642996A4 (en) PHARMACEUTICAL COMPOSITIONS